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Abstract Background
Invasive Fungal disease (IFD) is a disease of immunocompromised hosts.
Cytokines are important mediators of innate and adaptive immune system. The aim of this study was to identify cytokine profiles that correlate with increased risk of IFD.
Methods
We prospectively enrolled 172 adult haematology patients undergoing intensive chemotherapy, immunosuppressive therapy, and haematopoietic stem cell transplantation. Pro-inflammatory cytokine profiling using 30-plex Luminex assay was performed at baseline and during treatment. Nine single nucleotide polymorphisms (TLR1, TLR2, TLR3, TLR4.1, TLR4.2, TLR6, CLEC7A, CARD9, and INFG) were investigated among transplant recipients and donors.
Findings
The incidence of IFD in this cohort was 16.9 % (29/172). Median baseline serum concentrations of IL-15, IL-2R, CCL2, and MIP-1α were significantly higher whilst IL-4 was lower in patients with proven/probable IFD compared to those with no evidence of IFD. Baseline high IL-2R and CCL2 were associated with increased risk of IFD in the multivariate analysis (adjusted hazard ratio 2.3 [95% CI 1.1 -5.1; P = 0.037], and hazard ratio 2.7 [95% CI 1.2 -6.1; P = 0.016], respectively). However, these differences were not significant in follow up measurements. Similarly, no significant independent prognostic value was associated with baseline cytokine profile.
Interpretation
High baseline IL-2R and CCL2 concentrations were independent indicators of the risk of developing IFD and could be used to identify patients for enhanced prophylaxis and early antifungal therapy.
Introduction
Invasive fungal disease (IFD) remains an important cause of mortality and morbidity among haematology patients undergoing chemotherapy and haematopoietic stem cell transplantation (HSCT). [1] [2] [3] This is largely due to the a defective immune system caused by the underlying primary haematological malignancies and their often complex treatments. 4 IFD caused by moulds such as invasive aspergillosis (IA) are notoriously difficult to diagnose in clinical practice and indeed no validated standardised criteria exist for this purpose.
The ubiquitous nature of moulds makes human contact almost universal. Inhalation of asexual spores (conidia) brings them into contact with the respiratory macrophages and monocytes, which are the first line of defence against IFD. 5 These effector cells of the innate immune system respond to the presence of the conidia, in concert with neutrophils, by a variety of complex mechanisms such as phagocytosis and intracellularly destroying conidia, and aggregation around the conidia to prevent their germination.
5-7
The innate immune system relies on pattern recognition receptors (PRR) on the surface of immune cells, which recognise pathogenassociated molecular patterns (PAMP) on the surface of fungi and many other microorganisms. 8 The best characterised PAMPs involved in the recognition of fungi are Toll-like receptors (TLR) and lectin receptors such as dectin-1. 9 The PRR-PAMP interaction triggers a cascade of complex intracellular reactions leading to the production of pro-inflammatory cytokines such as TNF, IL-1, IL-12 and IL-6 via the nuclear factor-κB (NF-κB) pathway. 10 This in turn drives CD4+ T-lymphocytes towards T helper (Th) 1 and 17 phenotype, an adaptive immune response that further augments the innate immune system. 9, 11 M A N U S C R I P T have been shown to increase the risk of IFD through defective cytokine production. 14, 15 Polymorphisms in other cytokine genes such as IL-10, IL-1, TNF receptor type 2 promoter have also been implicated as genetic biomarkers of susceptibility to IFD. [16] [17] [18] However, the prevalence of such SNPs are relatively uncommon as the vast majority of IFD patients or stem cell donors do not have any identifiable mutation. It is therefore likely that other yet unidentified mechanisms exist which affects an effective cytokine milieu.
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As cytokines are key molecules that mediate and regulate effector functions of both the innate and adaptive immune systems, we hypothesise that serum cytokine levels pre-chemotherapy or HSCT (baseline cytokine profile) and levels during treatment may provide a diagnostic and prognostic value. As part of the Diagnostic and Management Strategies for Invasive Aspergillosis Study 19 we examined the role of cytokines in IFD as risk and prognostic factors by measuring 30 cytokines on sera at baseline and follow-up in a cohort of haematology patients undergoing HSCT or intensive chemotherapy. In addition, we examined nine previously reported polymorphisms associated with IFD that influence cytokine biology.
Patients and Methods
Patients
Study subjects were from the Diagnostic and Management Strategies for Invasive Aspergillosis (ClinicalTrials.gov NCT00816088).
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Only adult patients with haematological malignancy or aplastic anaemia undergoing intensive chemotherapy or HSCT with expected period of neutropenia of more than 10 days were included.
Details of patient inclusion and exclusion criteria are provided elsewhere. 19 Out of the 203 recruited patients, 31 were excluded due to fever (6) for medical research involving human subjects and registered with the ClinicalTrials.gov (NCT00816088).
Antifungal, chemotherapy, transplant and IST protocols
All patients received antifungal drugs according to local protocol previously Transplant regimens were fludarabine-based with T-cell depletion using either antithymocyte globulin (ATG) or alemtuzumab. 22 Immunosuppressive therapy for aplastic anaemia used the ATG/cyclosporine protocol. 23 Chemotherapy regimens used were disease dependent and agreed by a multi-disciplinary team.
Cytokine profiling
Thirty 
Genetic polymorphisms
Nine single-nucleotide polymorphisms (SNP) were analysed using TaqMan SNP Genotyping Assays (Applied Biosystems). Analysis was performed from genomic DNA isolated from whole peripheral blood. The following genes / SNP's (dbSNP ref 
Statistical analysis
Data on baseline serum cytokine concentrations were presented as median (IQR) and compared between patients with proven/probable IFD and those with no The analyses were performed using SPSS statistics version 20 (IBM Corporation, New York, USA). P values <0.05 were considered statistically significant.
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Results
Baseline cytokines
Baseline serum cytokine concentrations were available for 172 patients ( Table 1) . among the allogeneic HSCT patients giving an IFD incidence of 16.9 % (12/71).
This reflects the incidence in the larger cohort of the study population previously described. 19 Five cytokines were found to be significantly different between patients with proven/probable IFD compared to those with no evidence of IFD. Median concentrations of IL-15, IL-2R, CCL2, and MIP-1α were higher while IL-4 was lower in patients with proven/probable IFD compared to those with no evidence of IFD (Table 2 ).
The role of baseline cytokines as risk factors for IFD was assessed using Cox proportional hazard model previously described. 19 The median (IQR) CCL2 and IL-2R concentrations were 419.0 pg/ml (150.2-840.6 pg/ml) and 443. 
Follow-up cytokines
A total of 412 serum follow-up samples from the 172 patients who had evaluable baseline patients were analysed. The median number of follow up cytokine samples per patient was 2 (range 2-15). Overall no significant differences were detected between patients with IFD compared to those with no evidence of IFD (Supplementary Figures S1-S5 ). However, IL-2R was consistently higher in IFD patients and appeared to increase with longer follow up ( Figure S3 ). (Table 4) .
Genetic polymorphisms
Prognostic factors
Baseline cytokine serum levels were assessed as potential prognostic factors using the Cox regression model. 
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neutropenic setting. 29 In this study we demonstrated the usefulness of measuring baseline cytokines from peripheral blood (minimally invasive and convenient) as independent risk factors for IFD.
IFD is a disease of the immunocompromised and many risk factors have been described. [30] [31] [32] Recently we described additional risk factors such as baseline CT abnormalities, prolonged monocytopenia, and poor performance status. CCL2 was first identified as a monocyte chemoattractant and was initially named monocyte chemoattractant protein-1 (MCP-1). 36 High levels have been linked to the pathogenesis and spread of many cancers such as prostate, breast, and colorectal
13 cancer. [37] [38] [39] CCL2 is thought to stimulate the tumour microenvironment by a variety of mechanisms including direct stimulation of the tumour cells while preventing an effective immune response. 40, 41 This ineffective immune response is likely to underlie increased IFD in haematology patients with high baseline CCL2. This effect is independent of monocytopenia, which occurs during follow-up after the administration of chemotherapy or immunosuppressive therapy.
It could be argued that the cytokine milieu that predict IFD is non-specific for fungal pathogens as the signaling pathway involved in cytokine biology is shared with other micro-organisms such as bacteria. However, the limited number of bacteraemias (6 cases) in this study makes it difficult to assess the role of cytokines in bacterial sepsis especially as these were co-infections. Larger studies involving greater numbers of bacteraemia cases will be required to address this association. and CRP as poor prognostic factors. 43 Important differences exist between that study and the current one. Firstly, the Global Comparative Aspergillosis Study was a clinical trial comparing voriconazole v amphotericin B and the case definitions for proven and probable IA were based on earlier EORTC/MSG 2002 definitions. 44 Secondly, there was no comparator arm in that trial as the study entry criterion was proven/probable IA. It is therefore difficult to assign the cytokine dynamics to IA.
Thirdly, the baseline values in that study refers to IA prior to initiation of antifungal therapy, which is in contrast to true baseline values in the current study where the patients showed no clinical or biochemical signs of sepsis and prior to chemotherapy, transplant or IST. Finally, the persistently high CRP and IL-6 after initiation of antifungal therapy may mean that the affected patients were not responding to therapy. This is especially relevant in a disease that is difficult to diagnose and the majority of patients were probable cases, some of which would be unclassified on the revised EORTC/MSG definitions.
Genetic predisposition to IFD has generated a lot of interest recently. [12] [13] [14] 18, [45] [46] [47] The selection of nine genes to examine for this susceptibility was based on these studies.
No statistically significant associations were found between these previously described SNPs and susceptibility to IFD in our cohort. The reason for this is likely to be due to sample size and/or the small number of IFD cases in the cohort.
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In conclusion, we have demonstrated that high baseline IL-2R and CCL2 are independent indicators of the risk of IFD. High serum levels may reflect ineffective immune environment, which in concert with further immunosuppression during haematological treatment could lead to increased incidence of IFD. Although we used the 30-plex approach, the 2 cytokines can be incorporated into routine biochemistry laboratories.
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